FDA backs ResVita Bio's breakthrough therapy for rare Netherton Syndrome

ResVita Bio, a Berkeley-based therapeutics company, has reached a key milestone in developing RVB-003, a potential treatment for Netherton Syndrome. The US Food and Drug Administration (FDA) gave positive feedback on the therapy's development plan during a recent Pre-Investigational New Drug (Pre-IND) meeting. This rare genetic skin disorder currently has no approved treatments.

RVB-003 is a first-in-class inhibitor targeting KLK5/7 proteases, designed using machine learning and delivered through ResVita Bio's continuous protein therapy platform. The company's approach focuses on improving skin barrier function and reducing inflammation, which are critical for Netherton Syndrome patients.

The FDA's feedback confirmed alignment on nonclinical studies, manufacturing processes, and the design of the first-in-human clinical trial. Chad Miller, PhD, the company's Chief Technology Officer, stated that the strong agreement with regulators boosts confidence in moving RVB-003 toward clinical testing.

Preclinical studies showed promising results, with RVB-003 demonstrating both efficacy and a strong safety profile in disease models. However, as of early 2026, no patients have yet been treated with the therapy, as it remains in early preclinical development. ResVita Bio plans to submit an Investigational New Drug (IND) application in the first half of 2026, with initial clinical efficacy data expected by early 2027.

The company's research is funded through private investment and grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Netherton Syndrome, caused by mutations in the SPINK5 gene, is a chronic and often life-threatening condition with no existing FDA-approved therapies.

ResVita Bio's progress with RVB-003 marks a step toward a potential treatment for Netherton Syndrome. The planned IND submission in 2026 will determine whether the therapy can advance to human trials. If successful, it could become the first approved option for patients with this severe skin disorder.